Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-015457

Viridian Therapeutics, Inc.\DE · VRDN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Kyle Lefkoff
Director
Period of report
Feb 24, 2017
Accepted (ET)
Feb 28, 2017 · 6:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Feb 24, 2017S6,500$14.0388D488,031ISee Footnote
Common StockF3,F2Feb 27, 2017S1,500$13.791D486,531ISee Footnote
Common StockF4,F2Feb 28, 2017S2,258$13.543D484,273ISee Footnote
Common StockF5holding———1,607,437ISee Footnote

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses